Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia-Reference-Cited by-同舟云学术

Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia

Author:

Junnarkar Gunjan¹,Allphin Clark²,Profant Judi³,Steininger Teresa L.⁴,Chen Cuiping⁵,Zomorodi Katie⁶,Skowronski Roman⁷,Black Jed⁸⁹

Affiliation:

1. Pharmaceutical Development and Manufacturing Science, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

2. New Product and Technology Integration, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

3. Medical Affairs, Global Molecule Team, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

4. Medical Communications, Global Scientific Affairs, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

5. Neuroscience Clinical Pharmacology, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

6. Early Development and Clinical Pharmacology, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

7. Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

8. Stanford University Center for Sleep Sciences and Medicine, Palo Alto, CA, USA

9. Sleep and CNS Medicine, Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

Funder

Jazz Pharmaceuticals

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

Reference79 articles.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献